ITIF：2026年欧洲失去生物制药领导权的教训及其试图恢复的努力报告（英文版）

Europe’s biopharmaceutical leadership eroded due to detrimental policy choices such as stringent price controls that weakened innovation incentives. Global leadership then shifted to the United States, which had developed a more supportive environment.  Price controls come with major costs. Europe’s policies led to fewer new drugs, delayed drug launches, reduced R&D investment, and large losses in high-value life sciences jobs.  For patients, time to availability—measured from regulator